CIRM Funded Clinical Trials

Transplantation of CRISPR-CAS9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease

Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$8,389,407
Trial Sponsor:
University of California, San Francisco
Trial Stage: 
Phase 1
Trial Status: 
Launching
Targeted Enrollment:
N/A
ClinicalTrials.gov ID: